Catalent, Inc. (NYSE:CTLT) Q4 2023 Earnings Call Transcript

And I think the idea here is, to your point, the supply chain has leveled out. As I see it, I think, it’s more normalized with some products or they are not clearly fixed, not clearly fixed and we all set stuff on boats. So we have to look at the whole supply chain in totality, but I do believe there’s stencil opportunity sitting here looking at capital in total. And I don’t think there’s going to be a much — it’s a different team that’s going to be, commercial team is going to be going after receivables. That manufacturing team and the supply chain are going to be going after inventory.

Tim Daley: Great. Got it. Thanks for the time. Appreciate it.

Operator: Thank you. We have no further questions on the line. I will now hand back to Alessandro Maselli for closing remarks.

Alessandro Maselli: Thank you. I’d like to thank everyone on the Catalent team for their commitment to our customers and patients, as showcased by the delivery in partnership with our customers Sarepta Therapeutics of the first dose of LFDs gene therapy to a young child in the U.S. who’s suffering from DMD, making a historical milestone in the promise of treating these terrible condition. We remain focused on leading Catalent towards sustainable and profitable growth and increasing the shareholder value and I believe that actions announced today has placed us on a clear path to doing so. Thank you everyone for taking the time to join our call and your continued support of Catalent.

Operator: Thank you. Ladies and gentlemen, this concludes today’s call. Thank you for joining. You may now disconnect your lines.